Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Altesa BioSciences, Inc. currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are being handled by 3 distinct examiners and 3 distinct art units. This structure shows that each of the 3 pending office actions is being reviewed in a different technical context by a different patent office official.
MILLER, DALE R is the busiest examiner for this portfolio, currently managing 1 busiest examiner pending action. Since there are 3 distinct examiners for the 3 pending office actions, the workload is distributed such that no single person has a majority of the cases. This distribution requires the applicant to maintain three separate lines of communication within the Biotechnology & Pharmaceuticals field.
The involvement of 3 distinct art units suggests that the company's research and development efforts are being categorized into three distinct regulatory or technical paths. Managing 3 pending office actions across these diverse units requires a flexible legal strategy. The data indicates a balanced prosecution profile where each of the 3 distinct examiners plays an equal role in the current portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MILLER, DALE R | 1 | 62.5% | +17.6% |
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
| PATEL, SAGAR S | 1 | 75.7% | +34.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18604259 | METHOD OF TREATING ENTEROVIRUS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS | SZNAIDMAN, MARCOS L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18672122 | METHOD OF TREATING HEPATITIS C VIRUS IN PATIENTS | MILLER, DALE R | — |
| 18604259 | METHOD OF TREATING ENTEROVIRUS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS | SZNAIDMAN, MARCOS L | — |
| 18604264 | METHOD OF DOSING VAPENDAVIR TO TREAT ENTEROVIRUS INFECTIONS | PATEL, SAGAR S | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1628 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18672122 | METHOD OF TREATING HEPATITIS C VIRUS IN PATIENTS | MILLER, DALE R | 1693 | §103 | Non-Final OA | — | Pending | May 23, 2024 |
| 18604259 | METHOD OF TREATING ENTEROVIRUS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS | SZNAIDMAN, MARCOS L | 1628 | §102§103 | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18604264 | METHOD OF DOSING VAPENDAVIR TO TREAT ENTEROVIRUS INFECTIONS | PATEL, SAGAR S | 1626 | §102§103§112DP | Non-Final OA | — | Pending | Mar 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAltesa BioSciences, Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Dale R Miller has the most, with 1 of Altesa BioSciences, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
